ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
AssigneeSOTIO a.s.
InventorsKathleen McGinness, Charles Wilson, Brant Herrin, Gregory Motz
Life of this patent
Estimating the term…
Abstract
Disclosed herein are genetically engineered hematopoietic cells (e.g., genetically engineered hematopoietic stem cells, or genetically engineered immune cells), which co-express one or more co-stimulatory polypeptides with an anti-GPC3 chimeric antigen receptor (CAR), and uses thereof for enhancing T cell anti-tumor activity in a subject in need of the treatment.
Claims55
A genetically engineered hematopoietic cell, wherein the hematopoietic cell co-expresses:
- (i) a chimeric antigen receptor (CAR) polypeptide;
- wherein the CAR polypeptide comprises:
- (a) an extracellular antigen binding domain, wherein the extracellular binding domain is specific to glypican-3 (GPC3);
- (b) a transmembrane domain;
- and
- (c) a cytoplasmic signaling domain;
- and
- (ii) a co-stimulatory polypeptide, wherein the co-stimulatory polypeptide is a member of the B7/CD28 superfamily, a member of the tumor necrosis factor (TNF) superfamily, or a ligand thereof, wherein the co-stimulatory polypeptide is encoded by an exogenous nucleic acid.
The hematopoietic cell of claim 30, wherein the third exogenous nucleotide sequence encodes a ribosomal skipping site, which is a P2A peptide.
Dependencies are inferred from the claim text.